2.7
2023CiteScore
65th percentile
Powered by 
Completed peer reviews since:
June 5, 2020
AMR | Ongoing Call for Papers
Polymicrobial infections | Bacterial and Fungal Priority Pathogens | Prioritizing Diseases in Emergency Contexts
➔ Go to quick submission instructions ➔ Request additional information
Section Editor for Antimicrobial Resistance
Dr. Vijay Kothari, Nirma University - India
(ORCID | Scopus Author ID | ResearchGate | ReviewerCredits | About the Editor)
Article types
Short communication; Full research paper; Mini-review; Full-length review paper
Journal information
Impact Factor 2024: 2.5
Scimago - Journal & Country Rank | Web of Science - Master Journal List | About this journal
Publisher information
AboutScience
Polymicrobial Infections: Mechanisms, Diagnostics, and Clinical Implications
Polymicrobial infections, involving the simultaneous presence of multiple pathogenic organisms, are increasingly recognized in a wide array of clinical contexts — from chronic wounds and respiratory tract infections to intra-abdominal sepsis and biofilm-associated diseases. Despite their prevalence and impact, the complexity of host-pathogen and intermicrobial interactions in these infections remains incompletely understood.
In response, Drug Target Insights welcomes submissions contributions from researchers, clinicians, and interdisciplinary teams aimed to advance our understanding of the pathogenesis, detection, therapeutic strategies, and clinical management of polymicrobial infections.
Topics of interest include (but are not limited to):
- Molecular mechanisms and microbiome dynamics in polymicrobial infections
- Host immune responses to multi-pathogen challenges
- Diagnostic tools and technologies (e.g., metagenomics, multiplex PCR, NGS)
- Antimicrobial resistance in polymicrobial settings
- Biofilm and interspecies interactions
- Clinical case series and cohort studies
- Animal models and translational research
- Implications for infection control and antimicrobial stewardship
Bacterial and Fungal Priority Pathogens: Drug Targets, Resistance, and Novel Therapeutics
The global rise of antimicrobial resistance (AMR) presents an urgent threat to public health, with bacterial priority pathogens at the forefront of this crisis with the global burden of invasive fungal diseases rising, particularly among immunocompromised populations.
In response, Drug Target Insights welcomes submissions from microbiologists, infectious disease specialists, pharmacologists, epidemiologists, public health professionals, and interdisciplinary researchers focused on Bacterial and Fungal Priority Pathogens, addressing the urgent need for innovative strategies to combat antimicrobial resistance (AMR) and identify effective therapeutic targets.
Topics of interest include, but are not limited to:
- Global and regional surveillance of bacterial and fungal priority pathogens
- Epidemiology and global burden of priority bacterial and fungal diseases
- Mechanisms of antimicrobial and antifungal resistance, emerging resistance trends, and virulence factors
- Genomic epidemiology, molecular typing, and pathogen evolution
- Novel antimicrobial and antifungal agents, combination therapies, and development of innovative therapeutics
- Non-traditional strategies, such as bacteriophages, vaccines, and antimicrobial peptides
- Diagnostic innovations, rapid detection technologies, and addressing accessibility in low-resource settings
- Host-pathogen interactions, immunopathology, and immune responses
- Fungal infections and bacterial diseases in vulnerable populations (e.g., HIV, transplant, ICU, cancer, immunocompromised individuals)
- Surveillance systems, data gaps in disease reporting, and infection prevention and control measures
- Infection control, antifungal and antimicrobial stewardship programs
- Policy, stewardship, and global health perspectives on combating resistance
Prioritizing Diseases for Research and Development in Emergency Contexts: Implications for Drug Target Discovery
In an era increasingly marked by public health emergencies—ranging from pandemics and conflict-related outbreaks to climate-driven health crises—there is a critical need to systematically prioritize diseases for research and development (R&D). This prioritization is essential not only for equitable resource allocation, but also for accelerating the discovery and validation of effective drug targets.
We welcome original research, systematic reviews, perspectives, commentaries and case studies that explore frameworks, methodologies, and real-world applications for prioritizing diseases in emergency settings, with a focus on how these efforts inform and enhance drug discovery and therapeutic innovation.
Topic of interest are (but not limited to):
- Methodologies for disease prioritization in low-resource or emergency contexts
- Integrating epidemiological, economic, and social data for R&D prioritization
- The role of global and regional institutions (e.g., WHO, CEPI, GAVI) in disease prioritization
- Case studies from recent public health emergencies (e.g., COVID-19, Ebola, cholera, mpox)
- Ethical considerations in disease prioritization and resource allocation
- Leveraging genomics and systems biology to identify novel drug targets
- Impact of disease prioritization on antimicrobial resistance and neglected tropical diseases
- Equity, access, and representation in R&D prioritization decisions
- Policy recommendations for sustainable R&D pipelines in emergency settings
Previous call for papers (in progress)
